Associate Director, Oncology Department, Sir Mortimer B. Davis-Jewish General Hospital
Director of Medical Oncology, Department of Oncology, McGill University
Professor, Departments of Medicine and Oncology, McGill University
Georgetown University Medical School, Washington, DC
Case Western Reserve University, Cleveland, OH
Georgetown Division, D.C. General Hospital, Washington, DC
Georgetown University Hospital, Washington, DC
Instituto Nazionale Tumori, Milan, Italy
Medical Oncology; Breast cancer.
New anti-cancer drug development; Anti-cancer drug resistance; DNA repair; Chronic Lymphocytic Leukemia; Clinical research.
In addition to his clinic duties as a medical oncologist, Dr. Panasci has an active research program which is largely focused on the pharmacology of anticancer agents, including investigations of the development of new anticancer agents and the mechanism of chloroethylnitrosourea and nitrogen mustard drug resistance. His group is investigating the mechanism of resistance to the nitrogen mustards in patients with chronic lymphocytic leukemia (CLL) and are also determining the mechanism of the increased antitumour activity of SarCNU, a new nitrosourea. In addition, they are examining the expression of the EMT transporter which is responsible for SarCNU uptake in various cell lines, mechanisms of resistance to SarCNU and transport differences between normal and malignant tissues. Because of his laboratory's development of SarCNU, the compound has been tested at the National Cancer Institute of the United States.